Last reviewed · How we verify
Tacrolimus Inhalation Aerosol
At a glance
| Generic name | Tacrolimus Inhalation Aerosol |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) (PHASE3)
- Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients (PHASE1, PHASE2)
- A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tacrolimus Inhalation Aerosol CI brief — competitive landscape report
- Tacrolimus Inhalation Aerosol updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI